Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FM 101 - Future Medicine

Drug Profile

FM 101 - Future Medicine

Alternative Names: FM-101-Future Medicine

Latest Information Update: 17 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Future Medicine
  • Class Eye disorder therapies; Hepatoprotectants; Nucleosides; Small molecules
  • Mechanism of Action Adenosine A3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glaucoma
  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 10 Apr 2019 Preclinical trials in Non-alcoholic steatohepatitis in South Korea (PO)
  • 10 Apr 2019 Preclinical pharmacodynamics data in Non-alcoholic steatohepatitis presented at the International Liver Congress 2019 (ILC-2019)
  • 08 Jan 2019 Phase-I clinical trials in Glaucoma (In volunteers) in Netherlands (PO) (NCT03879928)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top